redensyl darkenyl
Reading Document
Medical Text Search
redensyl hair growth active ingredient mechanism
Medical Text Search
darkenyl hair pigmentation melanin active ingredient
GradeResponse
GradeResponse
The in-house database doesn't have specific entries for these cosmetic actives, so I'll answer from my own knowledge.
Redensyl & Darkenyl
These are two patented cosmetic actives developed by Givaudan Active Beauty (formerly Induchem), often combined in hair care formulations targeting both hair loss and premature graying.
Redensyl
Purpose: Hair regrowth / anti-hair loss
Key Ingredients:
- DHQG (Dihydroquercetin-glucoside) — a plant polyphenol (from larch tree)
- EGCG2 (Epigallocatechin gallate glucoside) — a green tea-derived polyphenol
- Glycine, zinc chloride, and a carrier (glycerin/water)
Mechanism of Action:
- Targets Outer Root Sheath (ORS) cells of the hair follicle, which are stem cell-like progenitor cells
- Activates the Wnt/β-catenin pathway — a key signaling cascade for follicle cycling
- Promotes transition from the telogen (resting) phase → anagen (growth) phase
- Reduces follicle inflammation via antioxidant activity
- Stimulates cell proliferation and reduces apoptosis in hair follicle cells
Evidence:
- A double-blind, placebo-controlled clinical study (Induchem, 2013) showed ~~9% increase in anagen hairs and significant reduction in telogen hairs after 84 days at 3% concentration
- Proposed as an alternative/complement to minoxidil, without the scalp irritation profile
Typical use concentration: 3%
Darkenyl
Purpose: Restoring/preserving natural hair color; anti-graying
Key Ingredients:
- Methylenedioxy-phenyl analogue: specifically 3,4-Methylenedioxyphenethylamine (DOPA) precursor pathway modulator
- Actually formulated around Acetyl Tyrosine (melanin precursor) + Darkenyl's proprietary blend targeting melanocyte stem cells (McSCs)
More precisely, Darkenyl is based on:
- N-Acetyl Tyrosine — direct precursor to DOPA → dopaquinone → melanin
- A peptide/plant extract blend that activates the Wnt signaling pathway in melanocyte stem cells
Mechanism of Action:
- Reactivates dormant melanocyte stem cells in the hair bulge region
- Boosts tyrosinase activity — the rate-limiting enzyme in melanin synthesis
- Increases production of eumelanin (black/brown pigment)
- Addresses the root cause of graying: exhaustion/dysfunction of McSCs
Evidence:
- Clinical studies by Givaudan showed a reduction in gray hair percentage and improved hair darkness after 3 months of use
- Assessed via phototrichogram and colorimetry
Typical use concentration: 2–3%
Comparison Table
| Feature | Redensyl | Darkenyl |
|---|---|---|
| Primary target | Hair loss / thinning | Premature graying |
| Cell target | ORS hair follicle stem cells | Melanocyte stem cells |
| Key pathway | Wnt/β-catenin, antioxidant | Wnt, tyrosinase activation |
| Key active | DHQG, EGCG2 | N-Acetyl Tyrosine + peptide blend |
| Phase targeted | Telogen → Anagen shift | Melanogenesis |
| Typical dose | 3% | 2–3% |
| Evidence level | Phase II clinical trial (manufacturer-funded) | Clinical trial (manufacturer-funded) |
Combined Use
Many hair serums combine both actives to simultaneously address hair density and color maintenance — particularly relevant in androgenetic alopecia and age-related graying. There is no known antagonism between the two; both work at the level of the hair bulge stem cell niche.
Caveats:
- Most clinical evidence is manufacturer-sponsored; independent peer-reviewed data is limited
- Neither is a pharmaceutical — they are cosmeceutical actives, so regulatory claims are restricted
- They do not reverse established scarring alopecia or complete melanocyte loss
This is a shared conversation. Sign in to Orris to start your own chat.